Topic
Private Credit Research
Within the private credit landscape, researchers emphasize the continued importance of private markets and direct lending as essential tools for diversifying portfolios amidst heightened geopolitical uncertainty and credit stress. While direct lending remains supported, analysts advocate for strict selectivity with a bias toward non-cyclical sectors and infrastructure for inflation-linked income. Credit strategies demonstrated resilience with positive returns in early 2026, though a more defensive posture is emerging through the prioritization of Relative Value and Fixed Income Relative Value sub-strategies. Solid corporate fundamentals and projected S&P 500 EPS growth of 20% support the credit outlook, even as high government deficits pose long-term risks to yields and necessitate a focus on shorter-duration fixed income. Additionally, the massive expansion in AI-related demand, with a projected $1.7 trillion TAM by 2030, and the evolution of biotech into a compounding asset class are creating new long-term investment opportunities for credit providers. Collectively, these insights suggest a research direction focused on resilient, innovation-driven sectors to navigate a goldilocks environment disrupted by macro volatility.
4511 reports available
All reports
Page 180 of 188
Two Things to Watch in the Coming Week
UBS · May 11, 2026
US Market Intelligence Morning Briefing
J.P. Morgan · May 11, 2026
Cenomi Centers 1Q26 Earnings Call Takeaways
Goldman Sachs · May 11, 2026
Metcash First Take
Goldman Sachs · May 11, 2026
Fluor Corporation 1Q26 Results - Worley Read Through
Goldman Sachs · May 11, 2026
Good Morning Mail
Goldman Sachs · May 11, 2026
BinDawood Holding 1Q26 Earnings First Take
Goldman Sachs · May 11, 2026
Americas Small Cap Research Summary
Barclays · May 11, 2026
China AIDC and Power Corporate Day Takeaways
Goldman Sachs · May 11, 2026
Korea and Taiwan: How to Manage AI-Driven Super Surplus
Goldman Sachs · May 11, 2026
Evaluating Execution Risk for Avexitide Phase 3 Readout in Post-Bariatric Hypoglycemia
Goldman Sachs · May 11, 2026
BioAge Labs R&D Day and NLRP3 Asset Analysis
Goldman Sachs · May 11, 2026
Fidelity National Information Services 1Q26 Takeaways
Goldman Sachs · May 11, 2026
Guide to US CPI Risks
Citi · May 11, 2026
Seronegative Approval Reinforces Vyvgart's MG Positioning
Goldman Sachs · May 11, 2026
Europe Capital Goods 1Q26 Heatmap and CNH Update
Goldman Sachs · May 11, 2026
Australian Morning Focus
ANZ · May 11, 2026
China Healthcare Services Drug Chains FY25 and 1Q26 Wrap Up
Goldman Sachs · May 11, 2026
Monday Movers Dissected
Citigroup Inc. · May 11, 2026
China Hospital Equipment Bidding Update April 2026
Goldman Sachs · May 11, 2026
Market Focus Shift from Buybacks to Capex
The Market Ear · May 11, 2026
US Market Intelligence Afternoon Briefing
J.P. Morgan · May 11, 2026
Software Squeeze Potential and Positioning Analysis
The Market Ear · May 11, 2026
Urban Company Earnings Review
Goldman Sachs · May 11, 2026